{"entity":{"id":"curium","kind":"company","name":"Curium","aka":[],"tldr":"Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.","summary":"Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. Nuclide links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.curiumpharma.com"}],"tags":[],"related":["lu-177","sm-153"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["lu177-psma-it"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06235151"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"radiopharma","website":"https://www.curiumpharma.com","investors":[],"funding":[]},"route":"/companies/curium/","neighbours":{"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/"},{"id":"sm-153","kind":"isotope","name":"Samarium-153","route":"/isotopes/sm-153/"},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"drug":[{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/"},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/"},{"id":"ga-67-citrate","kind":"drug","name":"Gallium citrate Ga-67","route":"/drugs/ga-67-citrate/"},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"},{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","route":"/drugs/in-111-pentetreotide/"},{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/"},{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/"},{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/"},{"id":"tc-99m-mdp","kind":"drug","name":"Technetium Tc-99m medronate (MDP)","route":"/drugs/tc-99m-mdp/"}],"trial":[{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/"}],"technology":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/"},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"bottleneck":[{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/"}],"section":[{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/"},{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/"},{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/"}]}}